Inactive matrix gla protein plasma levels are associated with peripheral neuropathy in Type 2 diabetes

A.C. Jeannin, J.E. Salem, Z. Massy, C.E. Aubert, C. Vemeer, C. Amouyal, F. Phan, M. Halbron, C. Funck-Brentano, A. Hartemann, O. Bourron*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Web of Science)

Abstract

Aims/Hypothesis

Diabetic peripheral neuropathy is a frequent and severe complication of diabetes. As Matrixgla-protein (MGP) is expressed in several components of the nervous system and is involved in some neurological disease, MGP could play a role in peripheral nervous system homeostasis. The aim of this study was to evaluate factors associated with sensitive diabetic neuropathy in Type 2 Diabetes, and, in particular, dephospho-uncarboxylated MGP (dp-ucMGP), the inactive form of MGP.

Methods

198 patients with Type 2 Diabetes were included. Presence of sensitive diabetic neuropathy was defined by a neuropathy disability score (NDS) >= 6. Plasma levels of dp-ucMGP were measured by ELISA.

Results

In this cohort, the mean age was 64+/-8.4 years old, and 80% of patients were men. Peripheral neuropathy was present in 15.7% of the patients and was significantly associated (r = 0.51, p

Conclusions

The association between diabetic neuropathy and the inactive form of MGP suggests the existence of new pathophysiological pathways to explore. Further studies are needed to determine if dp-ucMGP may be used as a biomarker of sensitive neuropathy. Since dp-ucMGP is a marker of poor vitamin K status, clinical studies are warranted to explore the potential protective effect of high vitamin K intake on diabetic peripheral neuropathy.

Original languageEnglish
Article number0229145
Number of pages13
JournalPLOS ONE
Volume15
Issue number2
DOIs
Publication statusPublished - 24 Feb 2020

Keywords

  • alpha
  • bone morphogenetic protein-2
  • cardiovascular risk
  • criteria
  • diagnosis
  • inhibition
  • nerve-conduction
  • prevalence
  • receptor
  • risk-factors
  • CRITERIA
  • DIAGNOSIS
  • RISK-FACTORS
  • BONE MORPHOGENETIC PROTEIN-2
  • RECEPTOR
  • ALPHA
  • PREVALENCE
  • NERVE-CONDUCTION
  • INHIBITION
  • CARDIOVASCULAR RISK

Cite this